In CML, this effect was less pronounced, possibly reflecting differences between BCR-ABL1+ myeloid and lymphoid leukemias or differences between CML in chronic versus more advanced stages57,58 with regards to IGF1/mTORC2 signaling. This evidence concerns the gene IGF1 and chronic myelogenous leukemia, BCR-ABL1 positive.